Brief: Acadia Pharmaceuticals Q3 EPS USD 0.2 Vs. IBES Estimate USD 0.14
06/11/2024 21:05
Nov 06 (Reuters) - Acadia Pharmaceuticals Q3 operating expenses USD 218.757 million. * Q3 net income USD 32.765 million vs. IBES estimate USD 24.5 million * Q3 pretax profit USD 38.806 million vs. IBES estimate USD 27 million * Q3 product sales USD 250.401 million vs. IBES estimate USD 248.8 million
Recent news on Acadia Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
U.S. STOCKS ON THE MOVE-Fortrea, Nuvation Bio, Acadia Pharmaceuticals
Acadia Pharma jumps after EU panel reverses opinion on neurological disorder drug
Brief: Daybu® (Trofinetide) Recommended For Approval In The European Union By CHMP